BioCentury
ARTICLE | Company News

GlaxoSmithKline endocrine/metabolic news

December 3, 2012 8:00 AM UTC

GlaxoSmithKline entered into a consent judgment with 38 state attorneys general to resolve allegations the pharma illegally promoted diabetes drug Avandia rosiglitazone. The pharma agreed to pay $90 million and post summaries of all its observational studies and meta-analyses of its diabetes drugs. The pharma will also be responsible for posting summaries of any sponsored clinical trials of diabetes products within eight months of trial's primary completion date. Avandia is an oral thiazolidinedione (TZD) peroxisome proliferation activated receptor (PPAR) gamma agonist to enhance insulin sensitivity. ...